1. Introduction {#sec1}
===============

Hip fractures are common in the elderly. With an aging population, the incidence of hip fractures is increasing \[[@B1], [@B2]\]. The incidence of hip fractures worldwide is estimated to be 2.6 million by 2025 and to exceed 7 million by 2050 \[[@B3]\]. Pneumonia and surgical site infections are common complications after surgery for hip fracture \[[@B4], [@B5]\]. These complications have been reported to increase mortality after surgery for hip fracture \[[@B6], [@B7]\].

Japanese herbal kampo medicines have become popular in Japan \[[@B8]\]. Hochu-ekki-to and Juzen-taiho-to are two major kampo medicines, which are used to treat immunocompromised individuals \[[@B9], [@B10]\]. Experimental studies have suggested that Hochu-ekki-to and Juzen-taiho-to can prevent infectious diseases through enhancing the immune system \[[@B11]--[@B15]\]. Although Hochu-ekki-to and Juzen-taiho-to may be promising to prevent infectious diseases, only a few small clinical studies \[[@B16]--[@B21]\] have been published to date.

The aim of the present study is to investigate the impact of Hochu-ekki-to or Juzen-taiho-to on postoperative infectious complications in patients undergoing surgery for hip fracture, using a nationwide inpatient database in Japan.

2. Materials and Methods {#sec2}
========================

The Institutional Review Board of the University of Tokyo approved this study. Informed consent was waived due to the anonymous nature of the data.

2.1. Data Source {#sec2.1}
----------------

Patient data were extracted from the Diagnosis Procedure Combination database, which is a nationwide administrative claims database with discharge abstracts representing approximately 50% of all admissions to acute care hospitals in Japan \[[@B22], [@B23]\]. The Diagnosis Procedure Combination database provides (i) patient demographic data, (ii) admission-precipitating diagnosis, preexisting comorbidities on admission, and complications during hospitalization coded with the International Classification of Diseases, Tenth Revision (ICD-10) codes, (iii) hospital identification number, (iv) dates of procedures performed and dates of medications administered, (v) discharge status, and (vi) dates of hospital or intensive care unit admission and discharge. Physicians in charge record data for diagnoses, comorbidities, and discharge status.

2.2. Patients {#sec2.2}
-------------

In the present study, patients were included if they (i) had a hip fracture (ICD-10 S720, S721, or S722) as the admission-precipitating diagnosis, (ii) underwent surgery (open reduction and internal fixation or hemiarthroplasty) for hip fracture, and (iii) were discharged between July 2010 and March 2014. Exclusion criteria included the following: (i) age \< 40 years; (ii) body mass index data being unavailable, less than 10 kg/m^2^ or more than 70 kg/m^2^; (iii) number of hospital beds being not available.

2.3. Exposure of Interest, Outcomes, and Other Variables {#sec2.3}
--------------------------------------------------------

The exposure of interest was whether patients received Hochu-ekki-to or Juzen-taiho-to within seven days of surgery. These patients were defined as the kampo group. Other patients were defined as the control group.

Assessed outcomes include infectious complications and in-hospital deaths. Infectious complications include surgical site infection (SSI, ICD-10, T793, or T814), hospital acquired pneumonia (J10--18), and sepsis (A40 or A41).

Other variables evaluated include age, gender, body mass index, comorbidities extracted using algorithms developed by Quan et al. \[[@B24]\], fracture location, type of surgery, days between admission and the surgery, treatment year, the volume of red cell transfusion, and anesthesia time. As an index for severity, use of mechanical ventilation, administration of catecholamines, administration of red cell transfusion, renal replacement therapy, and admission to a high intensity care unit such as an intensive care unit or high care unit within seven days of surgery are also extracted.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Continuous variables are presented as the average with the standard deviation. Categorical variables are presented as the number with a percentage. Differences in the baseline characteristics between the kampo group and control group are compared using standardized differences. A standardized difference \< 10% indicates a negligible imbalance in baseline characteristics between groups \[[@B25]\].

To estimate the probability that a patient would receive Hochu-ekki-to or Juzen-taiho-to medicine, a propensity score was calculated for each patient using a multivariable logistic regression for receiving kampo medicine. As independent variables, the baseline characteristics shown in [Table 1](#tab1){ref-type="table"} are incorporated. Patients who received kampo medicine were 1-to-1 matched with patients in the control group on the basis of nearest neighbor matching without replacement. The caliper was set at 20% of the standard deviation of the propensity score. Outcomes between the two groups were compared using Fisher\'s exact test. A *P* value \< 0.05 is considered statistically significant. Propensity score matching is performed using "Matching" package of R version 3.1.3 (The R Foundation, Vienna, Austria). All other analyses are performed using SPSS version 22 (SPSS Inc., Chicago, Illinois, US).

3. Results {#sec3}
==========

After inclusion and exclusion criteria were applied, a total of 201,900 patients were included in the analysis ([Figure 1](#fig1){ref-type="fig"}). Of these, 424 patients received Hochu-ekki-to (259 patients) or Juzen-taiho-to (165 patients) within seven days of surgery.

[Table 1](#tab1){ref-type="table"} shows a comparison of baseline characteristics of patients in the kampo group and the control group before and after propensity score matching. Before propensity score matching, patients in the kampo group were more likely to have chronic pulmonary disease, peptic ulcer, and malignancy. Anesthesia time was shorter and the amount of transfusion was less in the kampo group. After propensity score matching, baseline characteristics between the two groups are well balanced.

[Table 2](#tab2){ref-type="table"} shows outcomes comparing the two groups. After propensity score matching, neither infectious complications nor in-hospital death was significantly different between the groups.

4. Discussion {#sec4}
=============

In this retrospective study using a nationwide administrative database in Japan, postoperative use of Hochu-ekki-to or Juzen-taiho-to was not associated with decreased occurrence of postoperative infectious complications or in-hospital death for patients undergoing surgery for hip fracture.

Previous animal studies have suggested immunostimulating properties of Hochu-ekki-to and Juzen-taiho-to. However, only a few small clinical studies have been conducted. Hochu-ekki-to prevented immunosuppression induced by surgery \[[@B17]\] or inhibited rhinovirus infection in airway epithelium \[[@B18]\]. Clinical studies of Juzen-taiho-to have shown improved host immunity in patients with brain tumors \[[@B21]\] and a significantly decreased frequency of otitis media was in children \[[@B19], [@B20]\].

There are several possible explanations why the results of the present study failed to show a favorable effect of the drugs. First, the timing of administration of the kampo medicine may not be appropriate. In the present study, the kampo group received Hochu-ekki-to or Juzen-taiho-to within seven days of surgery, whereas patients received kampo medicine before surgery in a previous study \[[@B17]\]. Postoperative administration of kampo medicine may not sufficiently reduce postoperative infectious complications in patients undergoing surgery for hip fracture. Second, previous studies mainly included infection-prone patients. Although the patients in the present study were older (mean age more than 80 years), most of these patients may have been immunocompetent. Hochu-ekki-to or Juzen-taiho-to may be effective in immunocompromised patients. Lastly, the lack of a significant reduction in infective complications may be due to type II error. Further study, including larger numbers of patients, is warranted.

We acknowledge that the present study has several limitations. First, despite the use of propensity score matching, residual confounding may bias the results because of the retrospective nature of the study. Second, the study does not show a preventive effect for infectious complications of kampo medicine; however, the sample size may not be sufficiently large to detect a difference between the groups. Third, the database does not contain information before admission or after discharge. Patients may have had Hochu-ekki-to or Juzen-taiho-to before surgery or may have suffered from infectious complications after discharge. Fourth, patients who received Hochu-ekki-to or Juzen-taiho-to were from 238 of 1147 hospitals. The fact that patients who received these kampo medicines were from a relatively small fraction of hospitals may bias the results. Fifth, antibiotic usage was not accounted for in estimating the propensity score because it was difficult to differentiate antibiotics use for prevention from use for treatment.

In conclusion, postoperative Hochu-ekki-to or Juzen-taiho-to is not associated with a decrease in the occurrence of infectious complications after surgery for hip fracture. It is possible that receiving Hochu-ekki-to or Juzen-taiho-to only after surgery is not sufficient to prevent postoperative complications.
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###### 

Baseline characteristics before and after propensity score matching.

                                                                 Prematching cohort   Propensity score matched cohort                                           
  -------------------------------------------------------------- -------------------- --------------------------------- ------- --------------- --------------- ---------
  Age, years, mean (SD)                                          82.1 (9.5)           83.0 (8.0)                        0.110   83.2 (8.8)      83.0 (8.0)      0.022
  Gender, (Female)                                               158327 (78.6)        332 (78.3)                        0.007   334 (78.8)      332 (78.3)      0.011
  BMI, kg/m^2^, mean (SD)                                        20.6 (3.6)           19.7 (3.6)                        0.247   19.6 (3.4)      19.7 (3.6)      0.029
  Charlson comorbidity                                                                                                                                           
   Myocardial infarction                                         2702 (1.3)           3 (0.7)                           0.063   8 (1.9)         3 (0.7)         0.104
   Congestive heart disease                                      15246 (7.6)          30 (7.1)                          0.019   30 (7.1)        30 (7.1)        \<0.001
   Peripheral vascular disease                                   2766 (1.4)           10 (2.4)                          0.073   9 (2.1)         10 (2.4)        0.016
   Cerebrovascular disease                                       20739 (10.3)         34 (8.0)                          0.079   32 (7.5)        34 (8.0)        0.018
   Dementia                                                      26861 (13.3)         62 (14.6)                         0.037   68 (16.0)       62 (14.6)       0.039
   Chronic pulmonary disease                                     8368 (4.2)           35 (8.3)                          0.171   44 (10.4)       35 (8.3)        0.073
   Rheumatic disease                                             4194 (2.1)           10 (2.4)                          0.019   7 (1.7)         10 (2.4)        0.050
   Peptic ulcer                                                  7915 (3.9)           31 (7.3)                          0.147   31 (7.3)        31 (7.3)        \<0.001
   Liver disease                                                 9324 (4.6)           24 (5.7)                          0.047   31 (7.3)        24 (5.7)        0.067
   DM without complications                                      30028 (14.9)         50 (11.8)                         0.092   57 (13.4)       50 (11.8)       0.050
   DM with complications                                         5628 (2.8)           10 (2.4)                          0.027   11 (2.6)        10 (2.4)        0.015
   Hemiparaplegia                                                967 (0.5)            0 (0.0)                           0.098   2 (0.5)         0 (0.0)         0.097
   Renal disease                                                 8508 (4.2)           18 (4.2)                          0.001   21 (5.0)        18 (4.2)        0.034
   Malignancy                                                    8426 (4.2)           37 (8.7)                          0.186   35 (8.3)        37 (8.7)        0.017
   Metastatic cancer                                             953 (0.5)            10 (2.4)                          0.160   8 (1.9)         10 (2.4)        0.033
  Antibiotic use within 7 days of surgery                        186699 (92.7)        424 (100)                         0.398   386 (91.0)      424 (100)       0.444
  Mechanical ventilation within 7 days of surgery                784 (0.4)            0 (0.0)                           0.088   1 (0.2)         0 (0.0)         0.069
  Catecholamine use within 7 days of surgery                     11526 (5.7)          30 (7.1)                          0.055   26 (6.1)        30 (7.1)        0.038
  Transfusion within 7 days of surgery                           54494 (27.0)         131 (30.9)                        0.085   131 (30.9)      131 (30.9)      \<0.001
  Renal replacement therapy within 7 days of surgery             661 (0.3)            1 (0.2)                           0.017   2 (0.5)         1 (0.2)         0.040
  High intensity care unit admission within 7 days of surgery    8470 (4.2)           14 (3.3)                          0.047   10 (2.4)        14 (3.3)        0.057
  Fracture location                                                                                                     0.059                                   0.078
   Neck                                                          104352 (51.8)        232 (54.7)                                222 (52.4)      232 (54.7)       
   Intertrochanteric                                             92156 (45.7)         182 (42.9)                                187 (44.1)      182 (42.9)       
   Subtrochanteric                                               4968 (2.5)           10 (2.4)                                  15 (3.5)        10 (2.4)        
  Type of surgery                                                                                                       0.032                                   0.049
   Open reduction and internal fixation                          131393 (65.2)        270 (63.7)                                280 (66.0)      270 (63.7)       
   Hemiarthroplasty                                              70083 (34.8)         154 (36.3)                                144 (34.0)      154 (36.3)       
  Anesthesia time category, min                                                                                         0.113                                   0.078
   -120                                                          140345 (69.7)        310 (73.1)                                322 (75.9)      310 (73.1)       
   121--180                                                      46834 (23.2)         94 (22.2)                                 81 (19.1)       94 (22.2)        
   181--240                                                      9857 (4.9)           15 (3.5)                                  15 (3.5)        15 (3.5)         
   241-                                                          4440 (2.2)           5 (1.2)                                   6 (1.4)         5 (1.2)          
  Transfusion volume category, mL                                                                                       0.124                                   0.090
   0                                                             126060 (62.6)        243 (57.3)                                240 (56.6)      243 (57.3)       
   1--200                                                        6090 (3.0)           12 (2.8)                                  12 (2.8)        12 (2.8)         
   201--400                                                      32747 (16.3)         77 (18.2)                                 88 (20.8)       77 (18.2)        
   401--600                                                      23752 (11.8)         55 (13.0)                                 55 (13.0)       55 (13.0)        
   601-                                                          12827 (6.4)          37 (8.7)                                  29 (6.8)        37 (8.7)         
  Interval between admission and surgery, days, mean (SD)        5.3 (7.3)            5.7 (5.3)                         0.066   5.7 (4.7)       5.7 (5.3)       0.009
  Hospital volume of surgery for hip fractures/year, mean (SD)   224 (135)            215 (156)                         0.060   220.8 (124.1)   215.2 (156.1)   0.040
  Fiscal year                                                                                                           0.147                                   0.022
   2010                                                          29851 (14.8)         70 (16.5)                                 73 (17.2)       70 (16.5)        
   2011                                                          51846 (25.7)         121 (28.5)                                120 (28.3)      121 (28.5)       
   2012                                                          61030 (30.3)         101 (23.8)                                102 (24.1)      101 (23.8)       
   2013                                                          58749 (29.2)         132 (31.1)                                129 (30.4)      132 (31.1)       
  Academic hospital                                              9766 (4.8)           12 (2.8)                          0.105   10 (2.4)        12 (2.8)        0.030
  Transferred by ambulance                                       104264 (51.8)        217 (51.2)                        0.011   213 (50.2)      217 (51.2)      0.019
  Number of beds categories                                                                                             0.109                                   0.079
   -200                                                          27331 (13.6)         61 (14.4)                                 61 (14.4)       61 (14.4)        
   201--400                                                      86723 (43.0)         164 (38.7)                                167 (39.4)      164 (38.7)       
   401--600                                                      61855 (30.7)         149 (35.1)                                153 (36.1)      149 (35.1)       
   601--800                                                      18835 (9.3)          37 (8.7)                                  35 (8.3)        37 (8.7)         
   801-                                                          6732 (3.3)           13 (3.1)                                  8 (1.9)         13 (3.1)         

Numbers and percentages are presented unless otherwise stated. SD, standard deviation; SMD, standardized mean difference; BMI, body mass index; DM, diabetes mellitus.

###### 

Outcomes before and after propensity score matching.

                                          Prematching cohort   Propensity score matched cohort                                
  --------------------------------------- -------------------- --------------------------------- ------- --------- ---------- -------
  In-hospital death, *n* (%)              3552 (1.8)           8 (1.9)                           0.852   6 (1.4)   8 (1.9)    0.394
  Infectious complications, *n* (%)       4647 (2.3)           12 (2.8)                          0.578   6 (1.4)   12 (2.8)   0.234
   Hospital-acquired pneumonia, *n* (%)   2830 (1.4)           6 (1.4)                                   5 (1.2)   6 (1.4)     
   Surgical site infection, *n* (%)       1239 (0.6)           3 (0.7)                                   1 (0.2)   3 (0.7)     
   Sepsis, *n* (%)                        710 (0.4)            4 (0.9)                                   2 (0.5)   4 (0.9)     

[^1]: Academic Editor: Kenji Watanabe
